Vantive: A New Company Built On Our Legacy Baxter is on a journey to spin off our ~$5B Kidney Care segment into an independent, publicly traded company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve. We believe Vantive will not only build our leadership in the kidney care space, it will also offer meaningful work to those who join us. At Vantive, you will become part of a community of peop…